Faculty Opinions recommendation of Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

2013 ◽  
Author(s):  
Luca Persani
Keyword(s):  
Thyroid Cancer ◽  
Phase 1 ◽  
Anaplastic Thyroid Cancer ◽  
Phase 1 Trial ◽  
Ppar Γ ◽  
Multicenter Phase

scholarly journals Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

2013 ◽  
Vol 98 (6) ◽  
pp. 2392-2400 ◽  
Author(s):  
R. C. Smallridge ◽  
J. A. Copland ◽  
M. S Brose ◽  
J. T. Wadsworth ◽  
Y. Houvras ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Phase 1 ◽  
Anaplastic Thyroid Cancer ◽  
Phase 1 Trial ◽  
Ppar Γ ◽  
Multicenter Phase

Abstract 1278: Phase 1 study of CS-7017, an oral PPAR-γ agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer

2011 ◽  
Author(s):  
Robert C. Smallridge ◽  
John A. Copland ◽  
Marcia S. Brose ◽  
J. Trad Wadsworth ◽  
Yariv Houvras ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Phase 1 ◽  
Anaplastic Thyroid Cancer ◽  
Phase 1 Study ◽  
Ppar Γ

scholarly journals Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Blood ◽  
2013 ◽  
Vol 121 (5) ◽  
pp. 745-751 ◽  
Author(s):  
James L. Rubenstein ◽  
Jing Li ◽  
Lingjing Chen ◽  
Ranjana Advani ◽  
Jan Drappatz ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Phase 1 ◽  
Cns Lymphoma ◽  
Phase 1 Trial ◽  
Multicenter Phase ◽  
Key Points

Key Points Phase I study showed that intraventricular rituximab plus methotrexate is feasible and active in the treatment of refractory CNS lymphoma.

Sign in / Sign up

Export Citation Format

Share Document